



# Financial Tear Sheet


## Corporate Profile

Lombard Medical, Inc. is a medical device company focused on the \$1.7bn market for minimally invasive treatment of abdominal aortic aneurysms (AAAs). The Company has global regulatory approval for Aorfix™, an endovascular stent graft which has been specifically designed to treat patients with the broadest range of AAA anatomies, including aortic neck angulation up to 90 degrees. The Company has also achieved CE Mark for the Altura™ endograft system, an innovative ultra-low profile endovascular stent graft that offers a simple and predictable solution for the treatment of more standard AAA anatomies. Altura was launched in Europe in January 2016, with an international rollout planned for later in 2016.

Lombard Medical is based in Oxfordshire, UK, with its manufacturing and OUS administrative office in Oxfordshire, UK. Lombard Medical's shares trade on the NASDAQ Global Market under the symbol EVAR.

## Share Price Information

EVAR (Common Stock)	
Exchange	NASDAQ (US Dollar)
Financial Status Indicator	C
Price	\$0.44
Change (%)	▼ 0.01 (2.22%)
Volume	857
52 Week Low	\$0.40
Market Cap	\$12,577,853
Rolling EPS	-1.54
PE Ratio	0
Shares Outstanding	27,950,785
Data as of 09/22/17 4:00 p.m. ET	



## Recent News

Date	Title
09/20/17	Lombard Medical Appoints Jonathan Hornsby as Vice President, Sales & Marketing
09/13/17	Lombard Medical Announces Completion of Restructuring and Implementation of Strategic Plan to Achieve Profitability

## Upcoming Events

There are currently no events scheduled.

05/15/17 Lombard Medical Announces First Patient Enrolled and Treated in the ALTITUDE Registry for the Altura® Stent Graft System

## SEC Filings

Filing Date	Form
09/20/17	6-K
09/13/17	6-K
08/15/17	6-K
07/26/17	6-K

## Board of Directors

Raymond Cohen	Non-Executive Chairman
John Rush	Non-Executive Director
Michael Carrel	Non-Executive Director
Jonathan Chen	Non-Executive Director
HongBin Sun	Non-Executive Director

## Executive Management Team

Kurt Lemvigh	Chief Executive Officer
Peter Phillips	Chief Technology Officer

Data provided by Nasdaq. Minimum 15 minutes delayed.